Evaluating the Role of Wearable Technology and Patient-reported Outcomes to Monitor Physical Function Decline in Prostate Cancer Survivors
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- Cedars-Sinai Medical Center
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Physical function decline within 3 months from baseline
- Status
- Active, Not Recruiting
- Last Updated
- last year
Overview
Brief Summary
Prospective observational research study to evaluate the role of wearable activity monitors to predict physical function decline among prostate cancer survivors receiving ADT.
Detailed Description
Physical function is a known predictor of QOL in advanced prostate cancer patients and key measure of treatment tolerability. While treatment with Androgen Deprivation Therapy (ADT) improves survival, it is associated with significant toxicities that lead to physical function (PF) decline. The average age of incident prostate cancer is 66 years, and in this older group of men, chronic comorbid conditions often co-occur with diagnosis, further adding to the risk for PF decline. With over 2.9 million prostate cancer survivors in the US, there is an increasing demand for adequate symptom monitoring and PF assessment throughout cancer care. However, there are currently no validated methods to systematically evaluate and predict PF decline. Thus, the overarching objective of this proposal is to determine whether the use of wearable technology to monitor objective daily activity combined with routine symptom reporting can predict PF decline. To accomplish this, we propose a mixed-methods approach that will provide quantitative information to help identify PC survivors at higher risk for PF decline as well as a qualitative aim gain a deeper understanding of the perceived relationships that PC survivors have with their physical activity levels and treatment symptoms.
Investigators
Gillian Gresham
Assistant Professor
Cedars-Sinai Medical Center
Eligibility Criteria
Inclusion Criteria
- •Prostate cancer patients receiving ADT (+/- radiation) or planning to receive ADT. Start date of ADT must be planned for no more 7 days after baseline, or patients must have started ADT within 6 months prior to enrollment.
- •18 years or older
- •Ambulatory (use of walking aids, such as cane and rollator, is acceptable)
- •Access to a device that has the capability to sync to the Fitbit
- •Have an understanding, ability, and willingness to fully comply with study procedures and restrictions
- •English or Spanish speaking
- •Informed consent obtained from subject and ability for subject to comply with the requirements of the study.
Exclusion Criteria
- •Using a pacemaker, implantable cardiac defibrillator, neurostimulator, implantable hearing aids, cochlear implants, or other electronic medical equipment. However, removable hearing aids are permitted.
Outcomes
Primary Outcomes
Physical function decline within 3 months from baseline
Time Frame: 3 months
Patient-reported physical function defined as 5-point change in standardized NIH PROMIS t-scores (mean 50, SD: 10), where higher scores represent higher physical function)
Absolute change in average step counts at 3 months from baseline
Time Frame: 3 months
Change will be calculated based on difference in average weekly step count at baseline from the average weekly step count at end-of-study visit as measured using a Fitbit activity monitor where mean weekly Fitbit activity values will be calculated
Secondary Outcomes
- Mean change in Fitbit 24-hour activity(3 months)
- Key themes and concepts surrounding the relationships patients have with their treatment symptoms and how they affect their daily activity, as assessed in qualitative interviews.(3 months)